{"result": "(\"entity\"<|>SORIGUER F<|>PERSON<|>Soriguer F is a researcher involved in the study of diabetes prevalence in Spain, specifically in the Di@bet.es Study.)\n##\n(\"entity\"<|>GODAY A<|>PERSON<|>Goday A is a researcher associated with the CIBERDEM group, focusing on diabetes prevalence in Spain.)\n##\n(\"entity\"<|>CRESPO C<|>PERSON<|>Crespo C is a researcher who contributed to the SECCAID study on the costs of diabetes in Spain.)\n##\n(\"entity\"<|>SORIANO PERERA P<|>PERSON<|>Soriano Perera P is a researcher who has published work on the epidemiology of diabetes mellitus in Spain.)\n##\n(\"entity\"<|>GEDE P<|>PERSON<|>Gede P is a researcher involved in the Steno-2 randomized trial related to diabetes intervention outcomes.)\n##\n(\"entity\"<|>TANCREDI M<|>PERSON<|>Tancredi M is a researcher who studied excess mortality among persons with type 2 diabetes.)\n##\n(\"entity\"<|>OROZCO-BELTRAN D<|>PERSON<|>Orozco-Beltran D is a researcher who analyzed the evolution of diabetes mortality in Spain.)\n##\n(\"entity\"<|>CABEZAS-AGRÍCOLA JM<|>PERSON<|>Cabezas-Agrícola JM is a researcher who discussed trends in diabetes mortality in Spain.)\n##\n(\"relationship\"<|>SORIGUER F<|>CIBERDEM<|>Soriguer F is part of the CIBERDEM group studying diabetes prevalence in Spain<|>6)\n##\n(\"relationship\"<|>GODAY A<|>CIBERDEM<|>Goday A is part of the CIBERDEM group studying diabetes prevalence in Spain<|>6)\n##\n(\"relationship\"<|>CRESPO C<|>SECCAID<|>Crespo C contributed to the SECCAID study on the costs of diabetes in Spain<|>6)\n##\n(\"relationship\"<|>SORIANO PERERA P<|>CIBERDEM<|>Soriano Perera P is involved in diabetes epidemiology research within the CIBERDEM group<|>6)\n##\n(\"relationship\"<|>GEDE P<|>DIABETES MELLITUS<|>Gede P's research on diabetes intervention outcomes relates to the broader issue of diabetes mellitus<|>6)\n##\n(\"relationship\"<|>TANCREDI M<|>DIABETES MELLITUS<|>Tancredi M's study on excess mortality is directly related to the impact of diabetes mellitus<|>6)\n##\n(\"relationship\"<|>OROZCO-BELTRAN D<|>DIABETES MELLITUS<|>Orozco-Beltran D's analysis of diabetes mortality trends is related to the issue of diabetes mellitus<|>6)\n##\n(\"relationship\"<|>CABEZAS-AGRÍCOLA JM<|>DIABETES MELLITUS<|>Cabezas-Agrícola JM's discussion on diabetes mortality trends is related to the issue of diabetes mellitus<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: losua R, Cabrera de León A, et al. Factores de riesgo cardiovascular en España en la\nprimera década del siglo XXI: análisis agrupado con datos individuales de 11 estudios de base pobla-\ncional, estudio DARIOS. Rev Esp Cardiol. 2011; 64 (4): 295-304.\n\n\n\n5. Soriguer F, Goday A et al (grupo CIBERDEM). Prevalence of diabetes mellitus and impaired glucose\nglucose regulation in Spain: the Di@bet.es Study. Diabetologia 2012; 55(1): 88-93.\n\n\n\n6. Crespo C, Brosa M, Soria A, López-Alba A, López N, Soria B. Costes directos de la diabetes mellitus\ny de sus complicaciones en España (Estudio SECCAID: Spain estimated cost Ciberdem-Cabimer in\nDiabetes). Av.Diabetol. 2013; 29(6): 182-189.\n\n\n\n7. Soriano Perera P, De Pablos Velasco PL. Epidemiología de la diabetes mellitus. Endocrinol Nutr.\n2007; 54(Supl3): 2-7.\n\n\n\n8. Gede P, Oellgaard J, Cartensen B et al. Years of life gained by multifactorial intervention in pa-\ntients with type 2 diabetes mellitus and microalbuminuia: 21 years follow-up on the Steno-2 rando-\nmized trial. Diabetología. 2016; 59: 2298-2307.\n\n\n\n9. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabe-\ntes. N Eng J Med. 2015; 314: 1722-1732.\n\n\n\n10.  Orozco-Beltran D Sánchez E, Garrido A, Quesada JA, Carratalá-Munuera MC, Gil-Guillén VF. Evo-\nlución de la mortalidad por diabetes mellitus en España: análisis del periodo 1998-2013. Rev Esp\nCardiol. 2017; 70(6): 433-443.\n\n\n\n11.  Cabezas-Agrícola JM. Tendencias de la mortalidad por diabetes mellitus en España: por el buen\ncamino. Rev Esp Cardiol. 2017 70(6): 421-422.\n\n\n\n                                                                                                          35\n---\n     Artículos Especiales\n    Hacia la medicina de precisión\n    en diabetes                   mellitus\n    Dr. Juan Francisco Merino Torres\n    Jefe Servicio de Endocrinología y Nutrición.\n    Hospital Universitario y Politécnico La Fe, Valencia.\n\n\n\n             La diabetesmellitus se encuentra entre los problemas de salud más importan-\n    tes del siglo XXI. Datos del estudio di@bet.es muestran una prevalencia en nuestro me-\n    dio del 13,8%, estando aproximadamente el 6% sin diagnosticar. Además, con la edad\n    su prevalencia es mayor, superando en algunos estudios el 20% en mayores de 60 años.\n    El estudio Valencia limitado a la Comunidad Valenciana, encuentra datos similares, con\n    una prevalencia del 14%.\n\n\n\n             Así mismo, supone un importante impacto económico, a nivel mundial se estima\n    que el coste de la diabetes y su intervención alcanza un 11,6% del gasto en salud. En\n    España se estima que supone en torno al 8% del gasto sanitario público. Estas cifras\n    son aún más impactantes si tenemos en cuenta que es una enfermedad que se puede\n    prevenir con intervenciones dirigidas a prevenir la obesidad, buscar el normopeso, con\n    una modificación en los hábitos alimentarios y un incremento en la actividad física.\n\n\n\n             Actualmente, la medicina se encuentra en una importante fase de cambio. La\n    llegada de las tecnologías nos ha llevado a una transformación digital donde todo está\n    informatizado y se pueden manejar grandes cantidades de información. Esto está per-\n    mitiendo analizar los datos de manera diferente y hacer intervenciones en salud más\n    dirigidas. Estamos en la era de la Medicina de Precisión, estamos en la etapa de la “P”:\n    Una medicina Preventiva, Predictiva, Participativa, Poblacional y, sobre todo, Personali-\n    zada.\n\n\n\n             El Departamento de Salud La Fe lleva unos años haciendo una importante apues-\n    ta en este sentido. Se trata de un Departamento con una cápita de 300.000 habitantes,\n    con un hospital terciario, que es de referencia para toda la Comunidad Valenciana, 1\n    centro de especialidades y 20 centros de atención primaria. En el mismo se ha desa-\n    rrollado una Plataforma TIC en Salud, con análisis BIG DATA y Salud Digital, pero, ¿qué\n    quiere decir esto?\n\n\n\n             En la actualidad, todos los datos relacionados con salud están almacenados en\n    un soporte informático: la historia clínica del Hospital, los ingresos, las intervenciones,\n    la cirugía ambulatoria, la atención de urgencias, la historia clínica de atención prima-\n    ria, los estudios de anatom\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ESPAÑA<|>GEO<|>España is a country in Europe where various studies on diabetes and cardiovascular risk factors have been conducted.)\n##\n(\"entity\"<|>DARIOS<|>ORGANIZATION<|>DARIOS is a study that analyzed cardiovascular risk factors in Spain during the first decade of the 21st century.)\n##\n(\"entity\"<|>CIBERDEM<|>ORGANIZATION<|>CIBERDEM is a research network focused on diabetes and its complications in Spain.)\n##\n(\"entity\"<|>SECCAID<|>ORGANIZATION<|>SECCAID is a study that estimated the direct costs of diabetes mellitus and its complications in Spain.)\n##\n(\"entity\"<|>HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE<|>ORGANIZATION<|>Hospital Universitario y Politécnico La Fe is a tertiary hospital in Valencia, Spain, involved in diabetes research and healthcare.)\n##\n(\"entity\"<|>JUAN FRANCISCO MERINO TORRES<|>PERSON<|>Dr. Juan Francisco Merino Torres is the head of the Endocrinology and Nutrition Service at Hospital Universitario y Politécnico La Fe.)\n##\n(\"entity\"<|>VALENCIA<|>GEO<|>Valencia is a city in Spain where the Hospital Universitario y Politécnico La Fe is located and where diabetes prevalence studies have been conducted.)\n##\n(\"entity\"<|>DIABETES MELLITUS<|>EVENT<|>Diabetes mellitus is a significant health issue in the 21st century, with studies showing its prevalence and impact on healthcare costs.)\n##\n(\"relationship\"<|>DARIOS<|>ESPAÑA<|>DARIOS is a study conducted in Spain focusing on cardiovascular risk factors<|>7)\n##\n(\"relationship\"<|>CIBERDEM<|>ESPAÑA<|>CIBERDEM is a research network that operates in Spain to study diabetes and its complications<|>7)\n##\n(\"relationship\"<|>SECCAID<|>ESPAÑA<|>SECCAID is a study that estimates the costs of diabetes in Spain<|>7)\n##\n(\"relationship\"<|>HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE<|>JUAN FRANCISCO MERINO TORRES<|>Dr. Juan Francisco Merino Torres is the head of the Endocrinology and Nutrition Service at Hospital Universitario y Politécnico La Fe<|>9)\n##\n(\"relationship\"<|>HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE<|>VALENCIA<|>Hospital Universitario y Politécnico La Fe is located in Valencia, Spain<|>8)\n##\n(\"relationship\"<|>DIABETES MELLITUS<|>ESPAÑA<|>Diabetes mellitus is a major health concern in Spain, affecting a significant portion of the population<|>8)\n<|COMPLETE|>"}]}